Characterizing the willingness to undergo treatment in patients with alopecia areata

被引:0
|
作者
Lauren F. O’Connor
Kristen M. Wells
机构
[1] University of Virginia,School of Medicine, Department of Public Health Sciences
来源
Archives of Dermatological Research | 2022年 / 314卷
关键词
Alopecia areata; Hair; Patient needs; Treatment; Burden; Side effects; Hair regrowth; Treatment administration; Survey;
D O I
暂无
中图分类号
学科分类号
摘要
Alopecia areata is an autoimmune disease that results in partial or total balding of the scalp and/or body. Treatments available are minimally effective, have severe side effects, and are often painful. Given these burdens, patients may not feel undergoing treatment is worthwhile. The purpose of this study is to characterize the willingness of patients with alopecia areata to undergo treatment. We found that few patients are willing to undergo treatment at the risk of severe health side effects. The most acceptable form of treatment administration was topical and the least acceptable was injection at the site of hair loss. A majority of patients would only undergo treatment for hair growth that is cosmetically acceptable and the most important site of hair regrowth was the scalp. The willingness to undergo treatment differed significantly by gender, age, time since disease onset, and disease severity. This study offers insight into the preferences of patients with alopecia areata and characteristics that would make treatment widely acceptable. Institutions conducting research on treatment for alopecia areata can use the results of this study to better understand the needs of their target population.
引用
收藏
页码:749 / 757
页数:8
相关论文
共 50 条
  • [31] Tofacitinib as a treatment of alopecia areata in adolescents
    Morales-Miranda, Adalid Y.
    Bueno-Arias, Guadalupe M.
    Aguirre-Felix, Oscar G.
    Tovar-Franco, Rocio
    BOLETIN MEDICO DEL HOSPITAL INFANTIL DE MEXICO, 2019, 76 (04): : 182 - 187
  • [32] Alopecia Areata Update
    Alkhalifah, Abdullah
    DERMATOLOGIC CLINICS, 2013, 31 (01) : 93 - +
  • [33] Emerging drugs for the treatment of alopecia areata
    Ramirez-Marin, Hassiel Aurelio
    Tosti, Antonella
    EXPERT OPINION ON EMERGING DRUGS, 2022, 27 (04) : 379 - 387
  • [34] Bimatoprost versus Mometasone Furoate in the Treatment of Scalp Alopecia Areata: A Pilot Study
    Zaher, Hesharn
    Gawdat, Heba I.
    Hegazy, Rehab A.
    Hassan, Marwa
    DERMATOLOGY, 2015, 230 (04) : 308 - 313
  • [35] Alopecia areata: An update
    Seetharam, Kolalapudi Anjaneyulu
    INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2013, 79 (05) : 563 - 575
  • [36] Childhood alopecia areata
    Mazereeuw-Hautier, J.
    Maza-Rioland, A.
    Royer, M.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2012, 139 (02): : 151 - 155
  • [37] Treatment satisfaction and response in patients with severe alopecia areata under treatment with diphenylcyclopropenone
    Abedini, Robabeh
    Abdshah, Alireza
    Ghandi, Narges
    Janatalipour, Atefe
    Torabi, Sara
    Nasimi, Maryam
    HEALTH SCIENCE REPORTS, 2022, 5 (03)
  • [38] Response to ustekinumab in three pediatric patients with alopecia areata
    Aleisa, Abdullah
    Lim, Yeun
    Gordon, Samantha
    Her, Min Ji
    Zancanaro, Pedro
    Abudu, Minawaer
    Deverapalli, Sandhya Chowdary
    Madani, Abdulaziz
    Rosmarin, David
    PEDIATRIC DERMATOLOGY, 2019, 36 (01) : E44 - E45
  • [39] Latanoprost in treatment of alopecia areata and androgenic alopecia: A comprehensive review
    RAZI-KHOSROSHAHI, M. A. R. J. A. N.
    SOBHANI, S. O. H. E. I. L. A.
    YOUSEFI, K. I. M. I. A. M. O. Z. A. H. H. E. B.
    HAROONI, G. H. A. Z. A. L. E. H.
    MASHAYEKHI, F. A. R. Z. A. N. E. H.
    BALASI, J. A. V. A. D.
    GOODARZI, A. Z. A. D. E. H.
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2021, 15 (04): : 1535 - 1539
  • [40] Retrospective Evaluation of Alopecia Areata Patients
    Gonul, Muzeyyen
    Gul, Ulker
    Piskin, Emine
    Cakmak, Seray Kulcu
    Soylu, Secil
    Kilic, Arzu
    Biyikli, Zeynep
    TURK DERMATOLOJI DERGISI-TURKISH JOURNAL OF DERMATOLOGY, 2011, 5 (02): : 43 - 47